Former Oracle CTO Joe Alea Joins Clinical Ink as Chief Technical Officer

WINSTON-SALEM, NC and PHILADELPHIA, PA--(Marketwired - May 17, 2016) - Clinical Ink®, the top provider of cloud-based eSource and patient engagement solutions for clinical trials, today announced that Joe Alea has joined the company as Chief Technical Officer. Reporting to Clinical Ink's chief executive officer Ed Seguine and working from the Cambridge, MA location, Alea will head up all technology functions globally, playing a central role in the development and execution of the Company's overall product strategy and success.

"Well-designed and highly functional technology lies at the heart of our innovative approach to clinical research," said Clinical Ink CEO, Ed Seguine. "It's exciting for us to bring on a leader like Joe. He brings an impressive track record in developing successful product growth strategies that deliver distinctive value to life sciences and healthcare companies."

Clinical Ink solutions eliminate the need for EDC and on-site source data verification, allowing true remote monitoring saving time and money while increasing data quality. Capturing patient data electronically in real-time using SureSource® at clinical trial sites and CentrosHealth® for patients, ensures the reliability, quality, integrity, and traceability of data from electronic source to electronic regulatory submission, and delivers benefits that legacy technologies do not.

Alea has created enterprise and mission-critical systems for over 30 years with a philosophy that complex business problems deserve simple solutions that help drive adoption and utilization. He is known for delivering quality and timely products by creating effective teams and for following a disciplined engineering process. Before Clinical Ink, Alea served as senior vice president at Medicity, as CTO and SVP at Curaspan Health Group, and was vice president of development at Oracle Health Sciences, through the acquisition of Phase Forward. He has also held senior executive positions at Princeton Softech, Davox, and McKesson.

"I'm thrilled to be joining the Clinical Ink team at this time. The life sciences industry is entering an exciting era of technological disruption and Clinical Ink is well positioned to drive this important change for clinical trials around the world," Alea said. "I look forward to driving product innovations that help Clinical Ink's customers and partners evolve past legacy EDC technologies and improve the quality of the clinical trial experience for patients and sites."

Clinical Ink will spotlight results from its technology platform at a complimentary half-day eSource and Patient Engagement Symposium at the Ninety Acres Culinary Center in Peapack, New Jersey on June 7, 2016. Presenters will share client-based experiences of sponsors and sites regarding eSource and patient engagement technology adoption processes, best practices, and outcomes through case studies, panel discussions, and interactive participation. Register today!

About Clinical Ink

Founded in 2007, Clinical Ink® is transforming clinical development with innovative technologies that make clinical research easier for sites, sponsors and patients. Clinical Ink's SureSource® and CentrosHealth® solutions directly capture eSource data and documents and improve patient engagement while streamlining clinical development. Clinical Ink maintains offices in Cambridge, MA, Winston-Salem, NC, and Philadelphia, PA. Find more at www.clinicalink.com.